RayBiotech will leverage its antibody array diagnostics technologies to collect quantitative diagnostics information concerning key biochemical targets involved in human physiology and disease.
RayBiotech president COO and co-founder Rani Huang said the master service agreement will allow the company to exploit its antibody array diagnostics technologies in a services venue for the benefit of the partners.
"This agreement reflects our recently announced strategic focus on further expansion of our growth and development through a broadening of our portfolio of products and services, as well as, increased customer activities on a global basis," Huang added.